Vise Technologies Inc. Purchases New Holdings in Merit Medical Systems, Inc. $MMSI

Vise Technologies Inc. purchased a new position in Merit Medical Systems, Inc. (NASDAQ:MMSI) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 16,567 shares of the medical instruments supplier’s stock, valued at approximately $1,149,000.

Several other large investors have also recently modified their holdings of MMSI. Los Angeles Capital Management LLC purchased a new stake in Merit Medical Systems during the 4th quarter valued at about $25,000. Torren Management LLC purchased a new position in Merit Medical Systems in the fourth quarter worth about $38,000. Covestor Ltd lifted its stake in shares of Merit Medical Systems by 252.6% in the fourth quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 336 shares in the last quarter. Danske Bank A S bought a new position in shares of Merit Medical Systems in the third quarter worth approximately $42,000. Finally, Quarry LP grew its holdings in shares of Merit Medical Systems by 185.9% during the third quarter. Quarry LP now owns 526 shares of the medical instruments supplier’s stock valued at $44,000 after buying an additional 342 shares during the last quarter. Hedge funds and other institutional investors own 99.66% of the company’s stock.

Wall Street Analyst Weigh In

MMSI has been the subject of several analyst reports. Needham & Company LLC raised their price target on shares of Merit Medical Systems from $90.00 to $101.00 and gave the company a “buy” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. increased their target price on Merit Medical Systems from $77.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. BTIG Research reissued a “buy” rating and issued a $105.00 target price on shares of Merit Medical Systems in a report on Tuesday, August 11th. Wells Fargo & Company upped their price target on Merit Medical Systems from $74.00 to $83.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $100.00 price objective on shares of Merit Medical Systems in a research report on Friday, July 31st. Eight investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $100.00.

Merit Medical Systems Price Performance

Shares of Merit Medical Systems stock opened at $90.78 on Friday. The firm has a market cap of $5.42 billion, a PE ratio of 37.51, a P/E/G ratio of 2.28 and a beta of 0.49. The company has a quick ratio of 2.79, a current ratio of 4.20 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average price of $77.41 and a 200 day moving average price of $72.57. Merit Medical Systems, Inc. has a twelve month low of $59.74 and a twelve month high of $94.75.

Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.23. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. The business had revenue of $418.84 million for the quarter, compared to analysts’ expectations of $405.25 million. During the same quarter in the prior year, the company earned $1.01 earnings per share. The business’s quarterly revenue was up 9.5% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. Sell-side analysts predict that Merit Medical Systems, Inc. will post 3.81 earnings per share for the current fiscal year.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.